Vioxx Reps Will Shift To Vaccines In Second Half Of 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck expects to redeploy its Vioxx sales force to vaccines in the second half of 2005, the company said Dec. 14 during its annual business review in Whitehouse Station, N.J
You may also be interested in...
Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition
Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market
Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition
Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market
Merck Files ProQuad MMR/Varicella Combo Pediatric Vaccine
Company expects action on the BLA for a combination of its M-M-R II and Varivax vaccines by "early July" 2005. Three additional Merck vaccines are slated for submission over the next year, including agents for HPV and shingles.